Study to Evaluate Safety, Tolerability, Efficacy and Pharmacokinetics of ASC10 in Mild to Moderate COVID-19 Patients

Summary

This is a phase Ib, randomized, double-blind, placebo-controlled study to evaluate safety, tolerability, efficacy and pharmacokinetics of ASC10 tablets in mild or moderate COVID-19 subjects.

Timeline

Start

2022-11-28

Primary completion

2023-03-08

Completion

2023-10-09

Outcome

Outcome not reported

Stopped (Business): “This study has been cancelled due to business reasons.”

Drugs

Indications